Clear Search

Andrew Tutt, MB, ChB, PhD

The Institute of Cancer Research
London, United Kingdom

Titles and Affiliations

Head of Division of Breast Cancer Research
Director of Breast Cancer Now Research Centre
Professor of Clinical Oncology and Director of Breast Cancer Now Research Unit,
Division of Cancer Studies, King’s College London

Research area

Seeking to understand the factors associated with PARP inhibitor resistance and improve outcomes for breast cancer patients.


In normal cells, DNA damage is recognized and repaired so that they can continue to grow. However, in breast cancer cells with inherited mutations in genes such as BRCA1 or BRCA2, the ability to repair damaged DNA is impaired. This vulnerability in cancer cells has been exploited with treatments, such as PARP inhibitors which block alternative DNA repair processes these tumor cells depend on. Although these drugs are effective, tumor cells can further mutate to restore BRCA function and overcome the lethal effect of the therapy. Dr. Tutt and his team are studying this phenomenon and hope to define steps that can block it and reduce PARP inhibitor resistance and to design new ways to treat these drug resistant breast cancers.

Progress Thus Far

In laboratory studies, the team has found that the reactivated BCRF gene results in the production of a protein that is different from the normal protein, making it detectable by the immune system. They have begun to study this in patients by testing blood samples for evidence of an immune response against the tumor. The second line of research will involve isolating tumor cells from patients that develop PARP inhibitor resistance and grow them in the laboratory to study them in detail.

What’s Next

Dr. Tutt and his colleagues are continuing to search for evidence of an anti-tumor response in patient blood and will study how and where these immune cells become activated to target the cancer. They are also continuing to study patient tumors in the laboratory to understand the mechanisms of resistance to PARP inhibitor therapy. These efforts will help to define methods to release the brakes on the immune system so that PARP resistance can be prevented or to develop novel strategies to treat drug resistant tumors.


Andrew Tutt, MB, ChB, PhD is a Consultant Clinical Oncologist, Clinical Trialist, Laboratory Team Leader and Director of the breast cancer research teams at The Institute of Cancer Research in London, United Kingdom. He leads a team focused on understanding the fundamental biology and etiology of breast cancer molecular subtypes to inform the discovery and development of new therapeutics and biomarkers.

Dr. Tutt has made seminal contributions to the development of new therapies targeting aberrant DNA damage responses in breast and ovarian cancers. His clinical experience and expertise in basic cancer biology has driven the rapid translation of fundamental discoveries that have resulted in the development and licensing of new drugs and changed guidelines on genetic testing in oncology clinics. He has published a myriad of papers in prestigious journals such as Nature, The New England Journal of Medicine, The Lancet, Nature Medicine, Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Science Translational Medicine and Cancer Discovery. In recognition of his many achievements, Dr. Tutt has been awarded the Fellowship of the Academy of Medical Sciences, the Fellowship of the European Academy of Cancer Sciences, the 2021 ESMO Breast Cancer Award, and the 2022 AACR Team Science Award.

BCRF Investigator Since


Donor Recognition

The Estée Lauder Companies' UK & Ireland Award in Honor of Elizabeth Hurley